Skip to main content

NASDAQ:CTSO - Cytosorbents Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.67
  • Forecasted Upside: 88.76 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$8.30
▲ +0.17 (2.09%)
1 month | 3 months | 12 months
Get New Cytosorbents Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTSO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTSO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$15.67
▲ +88.76% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cytosorbents in the last 3 months. The average price target is $15.67, with a high forecast of $17.00 and a low forecast of $15.00. The average price target represents a 88.76% upside from the last price of $8.30.

Buy

The current consensus among 3 contributing investment analysts is to buy stock in Cytosorbents. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2021B. RileyBoost Price TargetOutperform ➝ Buy$16.00 ➝ $17.00N/A
i
Rating by A. D'silva at B. Riley
9/17/2020Jefferies Financial GroupInitiated CoverageBuy$15.00Medium
i
9/1/2020SVB LeerinkInitiated CoverageOutperform$15.00Medium
i
Rating by D. Antalffy at SVB Leerink LLC
7/23/2020B. RileyReiterated RatingBuyLow
i
Rating by A. D'silva at B. Riley
6/12/2020B. RileyInitiated CoverageBuy$16.00Medium
i
Rating by Andrew D'silva at B. Riley
5/7/2020Maxim GroupInitiated CoverageBuy$14.00Low
i
Rating by Jason McCarthy at Maxim Group
5/6/2020HC WainwrightBoost Price TargetBuy$13.00 ➝ $14.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/6/2020B. RileyBoost Price TargetBuy$12.00 ➝ $16.00High
i
Rating by Andrew D'silva at B. Riley
4/16/2020HC WainwrightReiterated RatingBuy$13.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/26/2020Maxim GroupReiterated RatingBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
3/9/2020Dawson JamesReiterated RatingBuy$15.00 ➝ $17.00High
i
3/6/2020HC WainwrightReiterated RatingBuy$13.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/27/2019B. RileyReiterated RatingBuy$12.00Low
i
Rating by Andrew D'silva at B. Riley
11/26/2019HC WainwrightReiterated RatingBuy$13.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/25/2019Maxim GroupReiterated RatingBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
10/21/2019B. RileySet Price TargetBuy$10.00Low
i
Rating by Andrew D'silva at B. Riley
8/7/2019HC WainwrightReiterated RatingBuyHigh
i
Rating by S. Ramakanth at HC Wainwright
8/7/2019Maxim GroupSet Price TargetBuy$14.00High
i
Rating by Jason McCarthy at Maxim Group
7/19/2019B. RileySet Price TargetBuy$12.00N/A
i
Rating by Andrew D'silva at B. Riley
5/8/2019Maxim GroupSet Price TargetBuy$14.00High
i
Rating by Jason McCarthy at Maxim Group
3/8/2019Maxim GroupReiterated RatingBuy$18.00High
i
Rating by Jason Kolbert at Maxim Group
3/8/2019HC WainwrightReiterated RatingBuy$15.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/14/2019HC WainwrightSet Price TargetBuy$15.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/20/2018Maxim GroupSet Price TargetBuy$10.00Low
i
Rating by Jason Kolbert at Maxim Group
11/7/2018HC WainwrightSet Price TargetBuy$15.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
9/4/2018Maxim GroupReiterated RatingBuy$18.00Low
i
Rating by Jason McCarthy at Maxim Group
8/3/2018CowenReiterated RatingBuy$15.00High
i
Rating by Josh Jennings at Cowen Inc
5/15/2018Maxim GroupSet Price TargetBuy$13.00High
i
Rating by Jason McCarthy at Maxim Group
5/9/2018Maxim GroupSet Price TargetBuy$12.00High
i
Rating by Jason McCarthy at Maxim Group
5/9/2018HC WainwrightReiterated RatingBuy$14.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/24/2018Maxim GroupSet Price TargetBuy$12.00High
i
Rating by Jason McCarthy at Maxim Group
3/9/2018HC WainwrightSet Price TargetBuy$14.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/9/2018Maxim GroupSet Price TargetBuy$12.00Medium
i
Rating by Jason Kolbert at Maxim Group
3/8/2018CowenSet Price TargetBuy$9.00Medium
i
Rating by Josh Jennings at Cowen Inc
1/25/2018B. RileyReiterated RatingBuy$11.25Low
i
Rating by Andrew D'silva at B. Riley
1/9/2018HC WainwrightReiterated RatingBuy$14.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/8/2018Maxim GroupSet Price TargetBuy$12.00N/A
i
Rating by Jason Kolbert at Maxim Group
12/22/2017B. RileySet Price TargetBuy$11.00High
i
Rating by Andrew D'silva at B. Riley
12/21/2017Maxim GroupSet Price TargetBuy$12.00High
i
Rating by Jason Kolbert at Maxim Group
12/11/2017Maxim GroupSet Price TargetBuy$12.00Low
i
Rating by Jason Kolbert at Maxim Group
11/21/2017HC WainwrightReiterated RatingBuy$13.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/10/2017B. RileyReiterated RatingBuy$11.25N/A
i
11/10/2017Maxim GroupReiterated RatingBuy$12.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/19/2017Maxim GroupSet Price TargetBuy$12.00N/A
i
Rating by Jason Kolbert at Maxim Group
9/26/2017HC WainwrightReiterated RatingBuy$13.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/12/2017B. RileyReiterated RatingBuy$11.25Low
i
8/8/2017HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/8/2017Maxim GroupBoost Price TargetBuy ➝ Buy$10.00 ➝ $12.00High
i
Rating by Gabrielle Zhou at Maxim Group
8/7/2017B. RileyReiterated RatingBuy$11.25Medium
i
8/2/2017B. RileyReiterated RatingBuy$11.25Medium
i
7/25/2017AegisReiterated RatingBuy$9.00High
i
Rating by J. Wittes at Aegis
7/17/2017Maxim GroupSet Price TargetBuy$10.00Medium
i
Rating by Gabrielle Zhou at Maxim Group
7/5/2017Maxim GroupReiterated RatingBuy$10.00Low
i
Rating by Gabrielle Zhou at Maxim Group
6/7/2017CowenInitiated CoverageOutperform$7.00High
i
5/22/2017Maxim GroupSet Price TargetBuy$10.00Medium
i
Rating by Gabrielle Zhou at Maxim Group
5/15/2017B. RileyReiterated RatingBuy$11.25Low
i
5/10/2017B. RileyReiterated RatingBuy$11.25Low
i
5/9/2017AegisReiterated RatingBuy$9.00High
i
Rating by J. Wittes at Aegis
5/6/2017Maxim GroupSet Price TargetBuy$10.00High
i
Rating by Gabrielle Zhou at Maxim Group
5/5/2017B. RileyReiterated RatingBuy$11.25Medium
i
4/25/2017Maxim GroupReiterated RatingBuy$10.00High
i
Rating by Gabrielle Zhou at Maxim Group
4/19/2017Maxim GroupReiterated RatingBuy$10.00High
i
Rating by Gabrielle Zhou at Maxim Group
4/11/2017B. RileyReiterated RatingBuy$11.25Low
i
Rating by A. D'silva at B. Riley
4/5/2017B. RileyReiterated RatingBuy$11.25Low
i
Rating by A. D'silva at B. Riley
3/22/2017Maxim GroupReiterated RatingBuy$10.00Medium
i
Rating by Gabrielle Zhou at Maxim Group
3/16/2017Maxim GroupReiterated RatingBuy ➝ BuyHigh
i
Rating by Gabrielle Zhou at Maxim Group
3/11/2017B. RileyReiterated RatingBuy$11.25N/A
i
Rating by A. D'silva at B. Riley
3/7/2017AegisReiterated RatingBuyLow
i
Rating by J. Wittes at Aegis
3/6/2017B. RileyReiterated RatingBuy$11.25N/A
i
Rating by A. D'silva at B. Riley
3/6/2017HC WainwrightBoost Price TargetBuy$11.50 ➝ $13.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/4/2017Maxim GroupSet Price TargetBuy$10.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
3/1/2017B. RileyReiterated RatingBuy$11.25N/A
i
Rating by A. D'silva at B. Riley
1/23/2017Maxim GroupBoost Price TargetBuy$8.00 ➝ $10.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
12/7/2016Maxim GroupSet Price TargetBuy$8.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
12/1/2016Maxim GroupSet Price TargetBuy$8.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
11/22/2016Maxim GroupSet Price TargetBuy$8.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
11/14/2016B. RileyReiterated RatingBuy$11.25N/A
i
Rating by A. D'silva at B. Riley
11/9/2016B. RileyReiterated RatingBuy$11.25N/A
i
Rating by A. D'silva at B. Riley
11/8/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/4/2016B. RileyReiterated RatingBuy$11.25N/A
i
Rating by A. D'silva at B. Riley
10/26/2016AegisInitiated CoverageBuy$20.00N/A
i
10/11/2016B. RileyInitiated CoverageBuy$11.25N/A
i
10/11/2016HC WainwrightSet Price TargetBuy$12.00N/A
i
10/6/2016B. RileyInitiated CoverageBuy$11.25N/A
i
Rating by A. D'silva at B. Riley
10/5/2016Maxim GroupReiterated RatingBuy$8.00N/A
i
10/4/2016Brean CapitalInitiated CoverageBuy$24.00N/A
i
9/8/2016Maxim GroupSet Price TargetBuy$8.00N/A
i
8/8/2016Maxim GroupReiterated RatingBuy$8.00N/A
i
7/17/2016Maxim GroupReiterated RatingBuy$8.00N/A
i
7/6/2016Maxim GroupReiterated RatingBuy$8.00N/A
i
6/15/2016Maxim GroupReiterated RatingBuyN/A
i
5/31/2016Maxim GroupReiterated RatingBuyN/A
i
5/24/2016Maxim GroupInitiated CoverageBuy$8.00N/A
i
(Data available from 5/16/2016 forward)
Cytosorbents logo
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
Read More

Today's Range

Now: $8.30
$8.11
$8.36

50 Day Range

MA: $8.80
$7.89
$9.42

52 Week Range

Now: $8.30
$7.13
$11.74

Volume

115,227 shs

Average Volume

323,412 shs

Market Capitalization

$359.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytosorbents?

The following Wall Street sell-side analysts have issued research reports on Cytosorbents in the last year: B. Riley, Jefferies Financial Group Inc., and SVB Leerink LLC.
View the latest analyst ratings for CTSO.

What is the current price target for Cytosorbents?

3 Wall Street analysts have set twelve-month price targets for Cytosorbents in the last year. Their average twelve-month price target is $15.67, suggesting a possible upside of 88.8%. B. Riley has the highest price target set, predicting CTSO will reach $17.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $15.00 for Cytosorbents in the next year.
View the latest price targets for CTSO.

What is the current consensus analyst rating for Cytosorbents?

Cytosorbents currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CTSO will outperform the market and that investors should add to their positions of Cytosorbents.
View the latest ratings for CTSO.

What other companies compete with Cytosorbents?

How do I contact Cytosorbents' investor relations team?

Cytosorbents' physical mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company's listed phone number is 732-329-8885 and its investor relations email address is [email protected] The official website for Cytosorbents is www.cytosorbents.com.